92 assets in Cholangiocarcinoma

Therapeutic assets addressing Cholangiocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P3	BB (64)
Irinotecan Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P3	B (63)
Docetaxel Cholangiocarcinoma	Merck Sharp & Dohme LLC	P2	B (62)
Oxaliplatin Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P3	B (62)
Nivolumab Cholangiocarcinoma	Instituto do Cancer do Estado de São Paulo	P2	B (61)
Capecitabine Cholangiocarcinoma	TransThera Sciences (Nanjing), Inc.	P3	B (60)
Cis-Diamminedichloroplatinum Ii Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P2	B (60)
Cediranib Cholangiocarcinoma	University of Southern California	P2	B (59)
Olutasidenib Cholangiocarcinoma	Rigel Pharmaceuticals	P4	B (59)
Pembrolizumab Cholangiocarcinoma	GV20 Therapeutics	P2	B (59)
Tinengotinib Cholangiocarcinoma	TransThera Sciences (Nanjing), Inc.	P3	B (59)
Carboplatin Cholangiocarcinoma	Merck Sharp & Dohme LLC	P2	B (58)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Cholangiocarcinoma	Toray Industries, Inc	P2	B (58)
Cyclophosphamide Cholangiocarcinoma	University of Pennsylvania	P2	B (57)
Durvalumab Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P2	B (57)
Fapi-46 Cholangiocarcinoma	University Hospital, Bordeaux	P2	CCC (55)
Fludeoxyglucose Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (55)
Ipilimumab Cholangiocarcinoma	TCR2 Therapeutics	P2	CCC (55)
Trastuzumab Cholangiocarcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (55)
Zimberelimab Cholangiocarcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (55)
Crgd-Zw800-1 Cholangiocarcinoma	Leiden University Medical Center	P2	CCC (54)
FAPI74 Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Floxuridine Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Fludarabine Cholangiocarcinoma	University of Pennsylvania	P2	CCC (54)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Cholangiocarcinoma	AHS Cancer Control Alberta	P2	CCC (54)
Lenvatinib Cholangiocarcinoma	Merck Sharp & Dohme LLC	P2	CCC (54)
N-Butyl Cyanoacrylate Cholangiocarcinoma	Minia University	P3	CCC (54)
Nilotinib Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Pembrolizumab/Vibostolimab Coformulation Cholangiocarcinoma	Merck Sharp & Dohme LLC	P2	CCC (54)
Atezolizumab Cholangiocarcinoma	Arbele Pty Ltd	P1/2	CCC (53)
Pevonedistat Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
[18f]f-resca-rt4 Cholangiocarcinoma	RenJi Hospital	P2/3	CCC (52)
[18F]F-RESCA-T4 Cholangiocarcinoma	RenJi Hospital	P2/3	CCC (52)
[68ga]ga-nota-rt4 Cholangiocarcinoma	RenJi Hospital	P2/3	CCC (52)
[68ga]ga-nota-t4 Cholangiocarcinoma	RenJi Hospital	P2/3	CCC (52)
Apsolol Cholangiocarcinoma	AHS Cancer Control Alberta	P2	CCC (51)
Dexasone Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Domvanalimab Cholangiocarcinoma	University of Texas Southwestern Medical Center	P2	CCC (51)
Entrectinib Cholangiocarcinoma	Hoffmann-La Roche	P2	CCC (51)
Kras Tcr-Transduced Pbl Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Olaparib Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (51)
pds01adc Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Rain-32 Cholangiocarcinoma	Rain Oncology Inc	P2	CCC (51)
Tislelizumab Cholangiocarcinoma	SOLTI Breast Cancer Research Group	P2	CCC (51)
Tucatinib Cholangiocarcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (51)
Certepetide Cholangiocarcinoma	Lisata Therapeutics, Inc.	P2	CCC (49)
Immunoglobulin G1 [351-Alanine,386-Alanine,387-Alanine] Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Imm2902 ?1-Chain), Disulfide With 1-125-Signal Regulatory Protein ? [80-Alanine] (Human Isoform 4 Variant) Fusion Protein With Peptide Linker ((Ggggs)3) Fusion Protein With Human-Mus Musculus Monoclonal Imm2902 ?-Chain, Dimer Cholangiocarcinoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1/2	CCC (48)
Pemigatinib Cholangiocarcinoma	Massachusetts General Hospital	P1/2	CCC (48)
Tipiracil Cholangiocarcinoma	Emory University	P1/2	CCC (48)
Trifluridine Cholangiocarcinoma	Emory University	P1/2	CCC (48)

Showing 1 to 50 of 92 assets

PreviousPage 1 of 2Next